In 2024, Zanrè et al. demonstrated that lamivudine, doravirine, and cabotegravir all downregulate the expression of HERV-K pol and env genes in melanoma cells, with cabotegravir exhibiting the most pronounced effect [161]. Here, ERVW-1 is linked to melanoma.